Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8789967 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
Increased EZH2 expression is associated with adverse pathologic features and inferior oncologic outcomes in patients with high-grade UTUC. The role of EZH2 biology in UTUC pathogenesis remains to be further elucidated.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Nirmish M.D., Laura-Maria M.D., Ahmet M. M.D., Vandana M.D., Solomon L. M.D., Yuval M.D., Christopher G. M.D., Jose A. M.D., Alon Z. M.D., Jay D. M.D., Mesut M.D., Nathalie M.D., Andrea M.D., Marco M.D., Christian M.D., Karim M.D., Arthur I. M.D.,